Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

promise BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management

Coordinator
Time Is Brain SL, Spain
Runs
1 May 2023 to 30 April 2026
Status
Running
EU funding
€2.5m
Total cost
€5.2m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190126352

What the project is doing

In the project's own words, from its summary on CORDIS.

Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20 is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients brain viability, thereby predicting who will benefit from EVT.

Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20 will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.

Topics

Who is involved

OrganisationCityCountryRole
Time Is Brain SLBadalonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI